Aligos Therapeutics, Inc. (ALGS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1248771,
    "name": "Aligos Therapeutics, Inc.",
    "stock_name": "Aligos Therapeutics, Inc.",
    "full_name": "Aligos Therapeutics, Inc.",
    "name_url": "stocks-analysis/aligos-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "10.09",
    "chg": 0.88,
    "chgp": "9.55%",
    "dir": 1,
    "prev_price": "9.21",
    "mcapval": "68.34",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US01626L1052",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "138.78 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aligos-therapeutics-inc-1248771-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Aligos Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-aligos-therapeutics-inc-technically-bullish-or-bearish-3547966",
        "imagepath": "",
        "date": "2025-09-20 20:06:54",
        "description": "As of 2 September 2025, the technical trend for Aligos Therapeutics, Inc. has changed from mildly bullish to mildly bearish. Currently, the weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are mildly bearish, suggesting short-term weakness. The Bollinger Bands show a mildly bullish stance on the weekly chart but are bearish on the monthly chart, indicating mixed signals. The KST is bullish weekly but bearish monthly, and the OBV is mildly bearish on the weekly timeframe.\n\nIn terms of performance, Aligos has significantly underperformed compared to the S&P 500, with a year-to-date return of -74.92% versus the S&P's 12.22%, and a one-year return of -29.45% compared to the S&P's 17.14%. Overall, the technical stance is mildly bearish, reflecting short-term weakness despite some longer-term bullish indicators...."
      },
      {
        "title": "Is Aligos Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-aligos-therapeutics-inc-overvalued-or-undervalued-3544163",
        "imagepath": "",
        "date": "2025-09-20 18:39:30",
        "description": "As of 5 August 2021, the valuation grade for Aligos Therapeutics, Inc. moved from does not qualify to risky, indicating increased concerns about its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.38 and an EV to EBITDA ratio of 1.07, which suggests that the market may be pricing in excessive optimism despite the company's losses. In comparison, peers like Checkpoint Therapeutics, Inc. and CASI Pharmaceuticals, Inc. have significantly worse valuation ratios, with EV to EBITDA ratios of -5.9896 and -1.1923, respectively, highlighting that Aligos is not the worst performer in its group despite its challenges.\n\nThe stock has underperformed against the S&P 500, with a year-to-date return of -74.92% compared to the index's 12.22%. This stark contrast reinforces the notion that Aligos Therapeutics is currently overvalued, as the market..."
      }
    ],
    "total": 6,
    "sid": "1248771",
    "stock_news_url": "https://www.marketsmojo.com/news/aligos-therapeutics-inc-1248771"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Aligos Therapeutics, Inc. technically bullish or bearish?

2025-09-20 20:06:54

As of 2 September 2025, the technical trend for Aligos Therapeutics, Inc. has changed from mildly bullish to mildly bearish. Currently, the weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are mildly bearish, suggesting short-term weakness. The Bollinger Bands show a mildly bullish stance on the weekly chart but are bearish on the monthly chart, indicating mixed signals. The KST is bullish weekly but bearish monthly, and the OBV is mildly bearish on the weekly timeframe. In terms of performance, Aligos has significantly underperformed compared to the S&P 500, with a year-to-date return of -74.92% versus the S&P's 12.22%, and a one-year return of -29.45% compared to the S&P's 17.14%. Overall, the technical stance is mildly bearish, reflecting short-term weakness despite some longer-term bullish indicators....

Is Aligos Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:39:30

As of 5 August 2021, the valuation grade for Aligos Therapeutics, Inc. moved from does not qualify to risky, indicating increased concerns about its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.38 and an EV to EBITDA ratio of 1.07, which suggests that the market may be pricing in excessive optimism despite the company's losses. In comparison, peers like Checkpoint Therapeutics, Inc. and CASI Pharmaceuticals, Inc. have significantly worse valuation ratios, with EV to EBITDA ratios of -5.9896 and -1.1923, respectively, highlighting that Aligos is not the worst performer in its group despite its challenges. The stock has underperformed against the S&P 500, with a year-to-date return of -74.92% compared to the index's 12.22%. This stark contrast reinforces the notion that Aligos Therapeutics is currently overvalued, as the market...

View All News